RSV IMMUNISATION FOR INFANTS IN EUROPE: ARE OUR HEALTH SYSTEMS READY?

Respiratory Syncytial Virus (RSV) is the most common cause of lower respiratory tract infections, including bronchiolitis and pneumonia, in infants. As RSV often leads to hospitalisation even for previously healthy infants, it causes major disruptions across health systems in Europe and is a key area of interest for health management. Following the work done for our white paper outlining the health system burden of RSV, and the recent approval of a new prophylactic monoclonal antibody for RSV, the European Health Management Association (EHMA) IS pleased to publish its white paper ‘RSV immunisation for infants in Europe: are our health systems ready?’. Based on expert insight from across Europe, this paper explores the challenges and opportunities of implementing RSV immunisation programmes in different country contexts.